Trademark: IMMUVANCE 2117020
Word
IMMUVANCE
ID
2117020
Trademark Type
Word
Status
Cancelled: Cancelled at the request of IB
Application Date
26 June 2020
Cancellation Date
13 June 2022
Owner(s)
Service
Davies Collison Cave Pty Ltd
Goods and Services:
Class 5:
Therapeutic preparations, namely, antibodies for use in targeting the C-C chemokine receptor type 5 [CCR5] cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19.
Therapeutic preparations, namely, antibodies for use in targeting the C-C chemokine receptor type 5 [CCR5] cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19.
Class 42:
Scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.
Scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.
Class 44:
Providing medical information, via a website; providing information in the field of using antibodies for medical treatment, for use in targeting the CCR5 cell receptor, via a website; providing health and medical information, via a website, namely, providing information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.
Providing medical information, via a website; providing information in the field of using antibodies for medical treatment, for use in targeting the CCR5 cell receptor, via a website; providing health and medical information, via a website, namely, providing information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.